Stomach acid pill may change how new myelofibrosis drug works
NCT ID NCT07608666
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 4 times
Summary
This early-stage study in 16 healthy adults checks if taking a common stomach acid drug (rabeprazole) changes how the body absorbs a new experimental drug (TQ05105) being developed for myelofibrosis. Participants take TQ05105 alone and later with rabeprazole to compare drug levels. The goal is to understand potential interactions, not to treat disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Third Xiangya Hospital, Central South University
Changsha, Hunan, 410013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- Can a new pill tame myelofibrosis?
- MRI as a window into bone marrow disease: a new biomarker test?
- Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
- Can a drug free myelofibrosis patients from frequent blood transfusions?
- Heart safety check for new myelofibrosis drug in healthy volunteers